Price board · 23 providers with a published semaglutide rate
Cheapest semaglutide when a quarter dose is the whole plan
Semaglutide is the molecule where a low dose is easiest to buy and easiest to overpay for. It is the cheaper of the two compounded GLP-1s almost everywhere, it is the one sold as a lozenge and as drops rather than only as an injection — and it is the one most often priced at a single flat rate, which is the structure that quietly charges a microdoser full price for a quarter of the drug.
Price is one axis. For a small dose, format is the other.
A quarter of an injection means drawing a partial unit into a U-100 syringe and trusting your eyes at the 2-unit mark. A quarter of a lozenge, or four drops instead of sixteen, is a different physical act with a different error bar. That is why injectable-only counts against a provider here and counts for nothing on a general weight-loss board, and it is why a sublingual row can sit near the top of this table on a price that looks unremarkable next to the injections.
The honest counterweight: absorption evidence for compounded sublingual and oral GLP-1 is thin. A format that is easier to divide is not automatically a format that delivers what the label says. We have written that out separately in do sublingual and troche microdoses actually work, and it is the reason the non-injectable rows are not simply promoted to the top of this table.
Every published semaglutide rate
23 providers · monthly cost
Partners first, then everyone else, as everywhere on this site and as described in our disclosure. Within each group, providers whose pricing falls with the dose come first. This is a partition and a structure sort — it is not sorted cheapest to dearest, and the cheapest figure on the page is not at the top.
Prices are printed exactly as the provider publishes them, with the conditions attached. An auto-refill rate, a prepay rate and a month-to-month rate are three different numbers and are shown as such rather than reduced to one. Verified against each provider's own site in 2026.
Who charges less for less
The same providers as the ladder above, regrouped by what their pricing does at a quarter dose. If you intend to titrate up to a standard dose, read the middle group as a feature rather than a fault — a flat rate is a promise that the bill will not climb with you. If you have decided to stay small, it is the group to walk past.
Charges less for less
8 providers
Publishes a named low-dose product at a lower price than its own full-dose equivalent. Taking a smaller amount genuinely costs less here, which is the structure this page is looking for.
Two named microdose programmes, each with its own flat monthly rate and a stated dose ceiling, priced beneath the full-dose market rather than as the bottom rung of one.
Launched a dedicated GLP-1 microdosing programme in Oct 2025; the row records the advertised entry rate as the microdose tier and realistic ongoing cost as meaningfully higher.
Sells microdosed tirzepatide as its own SKU, priced below its own full-dose tirzepatide — the row calls this the structure the site's rule was written to reward, and flags that every figure is an as-low-as tied to plan length.
Publishes a named Microdose line for both molecules on its own four-rung ladder, priced well beneath its own standard weight-loss line — the row records the month-to-month rung separately from the annual one because the marketing quotes the annual.
Sells a microdose program and a low-dose program as two distinct products at different prices, the microdose below the low-dose; the row flags that its per-month figure is the site's own amortisation of a charge that lands every two months.
Prices the low dose on its own
2 providers
Publishes a price for a microdose track, but no standard-dose price alongside it — so you can cost the low dose, you just cannot see what it saves you.
Publishes microdose tracks for both molecules at their own rate, with no standard-dose price alongside to compare against, and the visit billed separately.
Both molecules appear as named Microdose Programs with public from-prices, but the row records that no standard-dose figure could be read beside them and that the card never states what period either figure covers.
Same price at every dose
4 providers
One figure regardless of how much drug you take. Reassuring if you expect to titrate upward, and the least economical structure on this page if you do not: a quarter dose costs what a full one does.
Publishes one figure across its entire dose range for each molecule; the row calls the flat structure the least economical on the board for anyone staying small.
Its microdose line is flat at any strength, which the row scores as a cost rather than a comfort here: the flat microdose figure lands above the first rung of the provider's own published per-dose ladder, so taking less is billed at a premium.
The row records that microdose is a selectable dosage type inside the same product at the same from-price, so the bill does not fall when the dose does, and the only published term is a quarterly one paid up front.
Standard plan, self-directed low dose
9 providers
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
A generalist marketplace for real brand-name product with no dedicated microdosing programme — the row says starting low here means a low dose of a standard brand product.
The row states outright that this is standard-dose compounded GLP-1, not a dedicated microdosing programme, so starting low means self-directing inside a standard plan.
Low headline pricing on standard compounded plans in both injectable and oral formats, with no low-dose tier of its own and advertised prices described as floors.
All-inclusive pricing per format with no membership, but no separately published low-dose rate; the row also marks the figures company-stated rather than live-verified.
Prices by FORMAT rather than by dose — the row's point is that a drop or lozenge is a forgiving vehicle for a fraction of a dose, not that a fraction costs less.
Sells the sublingual lozenge at the same price as the injection, so the dose-flexible format costs nothing extra — but the price is per plan, not per dose.
Each price above is the provider's own published figure, printed word for word with the terms attached to it — a yearly-subscription rate and a month-to-month rate are not the same number and are not collapsed into one here. We do not publish a cost per milligram: that needs the vial strength and the milligrams dispensed per month, and most of these providers publish neither, so the arithmetic would be ours rather than theirs. Where a provider publishes no low-dose price at all, that is recorded as the finding rather than filled in with an estimate.
Top of the partner group
Ordered by pricing structure rather than headline figure, with the trade-offs on the card rather than behind it.
1
CoreAge Rx
Doctor-reviewed low-dose GLP-1 protocols with flat pricing and built-in human support.
U.S.-licensed clinicians review an online intake, then a low-dose GLP-1 protocol is filled by a 503A compounding pharmacy. CoreAge runs two longevity-oriented programs: a Semaglutide Microdose (up to 0.125 mg, $79/mo) and a Tirzepatide Microdose (dual GIP/GLP-1, up to 1.25 mg, $129/mo), framed for metabolic baseline and appetite — not aggressive weight loss. Every plan includes 1:1 nurse and registered-dietitian consults, an automatic refund if you are not approved, and roughly 2-business-day shipping. Monthly recurring, with no separate membership or lab fee.
Strengths
Transparent flat pricing — $79/mo semaglutide, $129/mo tirzepatide, with no membership or lab surcharge
Doctor-reviewed protocols filled by a 503A compounding pharmacy
Included 1:1 support from nurses and registered dietitians
Automatic refund if you are not approved for treatment
Explicit low-dose, longevity-and-metabolic framing rather than max-dose weight-loss marketing
Trade-offs
Focused on low-dose metabolic protocols — not a full-titration weight-loss clinic
Like all compounded GLP-1s, the product is not FDA-approved, and intentional microdosing is off-label and unproven (see our evidence review)
Start with CoreAge Rx — from $79/moMicrodosing is off-label and unproven — decide with a clinician. Prices verified in 2026; confirm current terms.
2
Found
Established, physician-designed weight-care telehealth with a broad formulary, real coaching, and a new GLP-1 microdosing program.
From $99/mo (compounded, varies)
Main trade-off: Compounded semaglutide/tirzepatide are not FDA-approved, and intentional microdosing is off-label and unproven
Full review — 6 strengths, 4 trade-offs+−
Pricing in full: Compounded semaglutide/tirzepatide from $99/mo (entry/microdose; realistic ~$199–$399/mo, cheapest tiers need 3–12-month prepay) · brand path (Wegovy/Ozempic/Zepbound/Mounjaro) adds ~$39/mo membership · oral Rybelsus available · HSA/FSA eligible
Found (joinfound.com, Found Health Inc.) has run physician-designed weight care since 2019 and reports 250k+ members. An intake is reviewed by obesity-medicine clinicians, then care is paired with a behavioral-coaching program — app, 1:1 coaching, and community — plus insurance navigation. The formulary is unusually broad: compounded semaglutide and tirzepatide, brand-name Wegovy/Ozempic/Zepbound/Mounjaro, oral Rybelsus, and even non-GLP oral options, prescribed in all 50 states. In October 2025 Found launched a dedicated GLP-1 microdosing program, which is directly relevant to a start-low approach. Pricing is layered rather than flat: a compounded entry advertised 'as low as $99/mo' (the microdose/entry tier), with realistic ongoing cost around $199–$399/mo, and the cheapest rates requiring a 3–12-month prepay; the brand pathway stacks a ~$39/mo membership on top.
Strengths
Established since 2019 with 250k+ members — a real track record, not a fly-by-night operator
Obesity-medicine clinicians, not just a prescription mill
Broad formulary: compounded semaglutide/tirzepatide, brand Wegovy/Ozempic/Zepbound/Mounjaro, and oral Rybelsus
Dedicated GLP-1 microdosing program (launched Oct 2025) suited to a start-low approach
Real behavioral coaching, app, and community alongside the medication
Insurance navigation, HSA/FSA eligibility, and prescribing in all 50 states
Trade-offs
Compounded semaglutide/tirzepatide are not FDA-approved, and intentional microdosing is off-label and unproven
Layered pricing: the $99/mo figure is the entry/microdose tier — realistic ongoing cost runs higher, and the cheapest rates require a 3–12-month prepay
The brand pathway stacks a ~$39/mo membership fee on top of the medication
Cost and coverage vary meaningfully by state and insurance plan
Visit FoundMicrodosing is off-label and unproven — decide with a clinician. Prices verified in 2026; confirm current terms.
Sells semaglutide, publishes no price
6 providers on our roster offer a semaglutide path and none of them let you see what it costs before an intake. One of them leads with a membership fee and another with a four-week intro rate; neither is the price of the medicine and neither should be read as one. They are named here rather than ranked, because a price nobody has seen cannot be called cheap or expensive.
Every page in this category, this one included, exists because compounded semaglutide undercut the brand by a wide margin during the shortage years. That gap has closed enough that the assumption now needs checking rather than repeating — and the evidence is on our own board, not in an outside source:
Real, FDA-approved brand-name GLP-1 through a cash-pay marketplace — e.g., the Wegovy oral pill from $149/mo — plus a separate Sesame platform subscription (two-part cost). Carries Wegovy (injectable pen + oral pill), Zepbound, Ozempic, Mounjaro, and oral Rybelsus.
Program $75 first month, then $149/mo ($75/mo annual) · compounded sema microdose $155/mo (standard $175) · brand Zepbound $349–$499 via Lilly
Both of those are real, FDA-approved product, and both land inside the compounded range on the ladder above. Compounded GLP-1 is not FDA-approved, is not the same medicine as Wegovy or Ozempic, and now competes on price rather than winning on it. If your dose is small enough, a brand pathway may cost you less than a compounded plan billed at a flat rate — which is not a sentence this site expected to be writing, and is the reason the brand rows stayed on the board.
The cheapest advertised monthly rate and the cheapest way to take a small dose are frequently different providers. A plan priced the same at every dose is good value if you titrate up to a full dose and poor value if you hold at a quarter of one. Look for a provider that publishes a low-dose tier below its own full-dose price, and check what terms are attached to the headline figure before comparing it with anything.
Is compounded semaglutide cheaper than Wegovy or Ozempic?
Not automatically, and that has changed recently. Brand-name self-pay pricing has come down far enough to overlap the compounded range — this site's own board carries a brand Wegovy oral pill from $149 a month and brand Zepbound at $349 to $499 through a manufacturer channel, which lands inside the range the compounded plans on this page occupy. Compounded product is also not FDA-approved and is not the same as the brand. Compare the two figures for your own dose rather than assuming.
Is sublingual semaglutide cheaper than the injection?
On this board one provider sells sublingual semaglutide below its own injectable price and another sells the lozenge at exactly the injection's price, so the format is not automatically a premium. What sublingual and drop formats genuinely change is not cost but divisibility: taking a fraction of a lozenge or counting drops is easier than drawing a partial unit into a syringe. The absorption evidence for non-injectable compounded GLP-1 is thin, which is the trade-off.
How small a dose of semaglutide is a microdose?
There is no official definition, because no regulator or trial has established one. In practice people use the term for amounts at or below the 0.25 mg starting dose used to introduce standard semaglutide therapy. That starting dose exists to limit side effects while titrating upward, not as a maintenance dose, so staying there indefinitely is off-label use of a step that was designed to be temporary.